71. Commonwealth Department of Human Services and Health (1995), Review of methadone treatment in Australia.
72. David C. L., Eric C. S., Robert K. B., et al. (2006), “HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate, buprenorphine, and methadone”, Journal of Substance Abuse Treatment, 31, pp. 187-194.
73. David C., Marsh M. D. (2012), History of Opioid Agonist Treatmen in Canada.
74. Department of Health and Human Services (2002), Methadone maintenance treatment.
75. Eugenia C., Ann B. B., Joseph H., et al. (2007), “The Vincent P. Dole Research and Treatment Institute for Opiate Dependence: An Integrated Biopsychosocial Model for the Treatment of Methadone Maintained Patients”, Heroin Addict Relat Clin Probl, 9(1), pp. 25-34.
76. Gibson R. D., Neil M. F., John J. M. (2002), “Effectiveness of
methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users”, AIDS 1999, 13(14), pp.
1807-1818.
77. Harm Reduction International (2008), The Global State of Harm Reduction 2008, mapping the response to drug-related HIV and hepatitis C epidemics.
78. Harm Reduction International (2010), The Global State of Harm Reduction 2010, key issues for broadening the response.
79. Harm Reduction International (2012), The Global State of Harm Reduction 2012 Towards an integrated response.
80. Harwood H. J., Hubbard R. L., Collins J. J., et al. (1988), “The costs of crime and the benefits of drug abuse treatment: a cost- benefit analysis using TOPS data”, Compulsory Treatment of Drug Abuse: Research and Clinical Practice, National Institute on Drug Abuse, pp. 209-234.
81. Joseph H., Stanclife S., Langrod J. (2000), “Methadone maintenance treatment: A Review of Historical and Clinical”, Issues The mount sinai journal of medicine, 67(5-6).
82. Hubbard R. L., Marsden M. E., Rachal J. V., et al. (1989), “Drug Abuse Treatment: A National Study of Effectiveness”, Chapel Hill:
University of North Carolina Press.
83. Hurley S. F., et al. (1997), “Effectiveness of needle-exchange programmes for prevention of HIV infection”, The Lancet, 21, pp. 349.
84. Maremani I. (2009), “The principles and practice of methadone treatment”, European Opiat addiction treatment Association.
85.
Jamieson., Beals., Lalonde., et al. (2002), “Best Practices Methadone Maintenance Treatment”, Office of Canada’s Drug Strategy Health Canada.
86. Luce J., Strike C. (2011), A Cross-Canada Scan of Methadone Maintenance Treatment Policy Developments.
87. Jarlais D., et al. (2005), “Reductions in hepatitis C virus and HIV
infections among injecting drug users in New York City, 1990 - 2001”, AIDS 2005, 19 (3).
88. Ward J. (2002), “Justifying drug substitution therapies: The case of methadone maintenance treatment”, School of Psychology Australian National University.
89. John P. W. (2001), “Drug Treatment in the Criminal Justice System”, Office of National Drug Control Policy.
90. Karen R. D., Susan C. W. (1999), “The Effectiveness of Condoms in Reducing Heterosexual Transmission of HIV”, Family Planning Perspectives, 31 (6).
91. Kylie V. (2007), Methadone Maintenance Treatment and Making Up People, University of New South Wales.
92. Lee Shui-shan. (2005), The contribution of methadone maintenance treatment to HIV prevention the case of Hong Kong.
93. Lin P., Yang., Guodong M., et al. (2007), “Effectiveness of first eight methadone maintenance treatment clinics in China”, AIDS 2007, 21 (8), pp. 103-107.
94. Marc R. (1999), “Methadone Treatment and spread of AIDS in Europe in the 1987-1993 years”, Heroin Add & Rel Clin Probl, 1(2), pp. 19-26.
95. McGlothlin W. H., Anglin M. D. (1981), “Shutting off methadone:
cost and benefits”, Archives of General Psychiatry, 38, pp. 885-892.
96. Metzger D. S., Woody G. E., McLellan A. T., et al. (1993), “Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up”, Journal of Acquired Immune Deficiency Syndrome, 6, pp. 1049-1056.
97. Miranda W. L., Brussel G., Coutinho R. A., et al. (2002),
“Methadone maintenance and cessation of injecting drug use: results from the Amsterdam Cohort Study”, Addiction, 95 (4), pp. 591-600.
98. McArthur M. (1999), A history of Methadone treatment in Australia:
The influence of social control arguments in its development, Australian Catholic University .
99. National AIDS Committee Thailand. (2012), Thailand AIDS Response Progress Report 2012, Reporting period: 2010-2011.
100. National Institutes on Drug Abuse (2010), The science of addiction.
101. NIDA (2002), Principles of HIV Prevention in Drug Using Populations.
102. Organisation of the Royal PharmaceuticalSociety of Great Britain (2009), Martindale: The Complete Drug Reference, Thirty-sixth edition.
103. Richard H., Needle., Burrows D., et al. (2005), Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users, International Journal of Drug Policy.
104. Robert H. (1998), “Syringe Exchange Programs: Lowering the transmission of syringe borne diseases and beyond”, Public Health report, 113.
105. Saskatchewan Health (2004), Methadone Assisted Recovery Guidelines For Addiction Counsellors, Healthy People, A Healthy Province.
106. Simpson D. D., Sells S. B. (1982), “Effectiveness of treatment for drug abuse: an overview of the DARP research program”, Psychology of Addictive Behaviors, 7(2), pp. 120-128.
107. Simpson D. D., Sells S. B. (1990), “Opioid Addiction and Treatment:
A 12-Year Follow-Up”, Malabar, FL: Krieger Publishing Company.
108. Stewart B. L. (2004), Methadone maintenance treatment.
109. Susan L., Coyle., Richard H., et al (1998), “Outreach-based HIV prevention for injecting drug users: a review of published outcome data”, Public Health Rep, 113(1), pp. 19-30.
110. Fraser S., Valentine. K., Treloar C., et al. (2007), Methadone maintenance treatment in New South Wales and Victoria: Takeaways, Diversion and other key issues.
111. The College of Physicians of Ontario (2005), Methadone maintenance guidelines.
112. Tinsman P. D., Bullman S., Chen X., et al. (2001), “Factors affecting
client response to HIV outreach efforts”, Journal of Substance Abuse, 13(1-2), pp. 201-214.
113. UNAIDS (2000), Evaluation of the 100% Condom Programme in Thailand.
114. UNAIDS (2011), World AIDS Day Report.
115. UNAIDS (2012), Together We Will End AIDS.
116. University of Victoria (2010), Methadone Maintenance Treatment in British Columbia, 1996-2008: Analysis and Recommendations.
117. UNODC (2012), World drug report 2012.
118. UNODC (2013), World drug report 2013.
119. U.S. Department of health and human services (2005), Medication Assisted Treatment For Opioid Addiction in Opioid Treatment Programs.
120. U.S. Global health policy (2012), The Global HIV/AIDS Epidemic.
121. Vincent P. D. (1965), A Medical treatment for diacetylmorphin (heroin) Addiction: A Clinical trial with methadone hydrocloride.
122. Vincent P. D. (1988), “Implications of Methadone Maintenance for Theories of Narcotic Addiction”, JAMA, 260, pp. 3025-3029.
123. Vincent P. D., Marie E. N. (1967), “Heroin Addiction – A Metabolic Disease”, Arch Intern Med, 120.
124. Wayne Hall. (1995), The demand for Methadone maintenance treatment in Australia, National Drug and Alcohol Research Centre, University of New South Wales
125. Wayne Hall. (1996), Methadone Maintenance Treatment as a Crime Control Measure, National Drug and Alcohol Research Centre.
126. Weller S. C., Davis-Beaty K. (2007), Condom effectiveness in reducing heterosexual HIV transmission (Review). The Cochrane Collaboration.
127. WHO (2004), Experiences of 100% condom use programme in selected countries of Asia.
128. WHO (2004), Neuroscience of psychoactive substance use and dependence.
129. WHO (2004), Policy Brief: Reduction of HIV transmission through.
outreach, Evidence for action on HIV/AIDS and injecting drug use.
130. WHO (2009), Good Practice in Asia: Targeted HIV prevention for injecting drug users and sex workers, Vietnam’s first large scale National Harm Reduction initiative.